Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000450:Aldosterone / Q000652:urine; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D005260:Female; D005542:Forearm / Q000098:blood supply; D005919:Glomerular Filtration Rate; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000652:urine; D010880:Piperidines / Q000627:therapeutic use; D011187:Posture; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012964:Sodium / Q000378:metabolism; D014636:Valsalva Maneuver; D014642:Vanilmandelic Acid / Q000652:urine; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D010880:Piperidines; D011743:Pyrimidines; D014665:Vasodilator Agents; D000450:Aldosterone; D014642:Vanilmandelic Acid; D012964:Sodium; D011433:Propranolol; D009638:Norepinephrine